Fan CQ, Crawford JM. Sinusoidal obstruction syndrome (hepatic veno-occlusive disease). J Clin Exp Hepatol. 2014;4(4):332–46.
Article PubMed PubMed Central Google Scholar
Arai S. Long-awaited news for hepatic veno-occlusive disease. Blood. 2016;127(13):1630–1.
Article CAS PubMed Google Scholar
Wu F, Yu J, Gan H, Zhang H, Tian D, Zheng D. Timing and efficacy of transjugular intrahepatic portosystemic shunt in patients with pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome. Sci Rep. 2021;11(1):21743.
Article CAS PubMed PubMed Central Google Scholar
Wang JY, Gao H. Tusanqi and hepatic sinusoidal obstruction syndrome. J Dig Dis. 2014;15(3):105–7.
Lin G, Wang JY, Li N, Li M, Gao H, Ji Y, et al. Hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum. J Hepatol. 2011;54(4):666–73.
Helmy A. Review article: updates in the pathogenesis and therapy of hepatic sinusoidal obstruction syndrome. Aliment Pharmacol Ther. 2006;23(1):11–25.
Article CAS PubMed Google Scholar
Yang XQ, Ye J, Li X, Li Q, Song YH. Pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome: Pathogenesis, clinical manifestations, diagnosis, treatment, and outcomes. World J Gastroenterol. 2019;25(28):3753–63.
Article PubMed PubMed Central Google Scholar
Zhou CZ, Wang RF, Lv WF, Fu YQ, Cheng DL, Zhu YJ, et al. Transjugular intrahepatic portosystemic shunt for pyrrolizidine alkaloid-related hepatic sinusoidal obstruction syndrome. World J Gastroenterol. 2020;26(24):3472–83.
Article PubMed PubMed Central Google Scholar
Peng C, Zhang X, Zhang F, Liu L, Shao Y, Xiang X, et al. Clinical efficacy and safety of anticoagulation therapy for Pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome: a retrospective multicenter cohort study. Eur J Gastroenterol Hepatol. 2020;32(9):1168–78.
Article CAS PubMed Google Scholar
Jiang M, Wang L, Du X, Hao M, Gao P. Low molecular weight heparin in the treatment of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome: five case reports. J Int Med Res. 2020;48(9):300060520961916.
Wang X, Zhang W, Zhang M, Zhang F, Xiao J, Yin Q, et al. Development of a drum tower severity scoring (DTSS) system for pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome. Hepatol Int. 2022;16:669.
Wang Y, Qiao D, Li Y, Xu F. Risk factors for hepatic veno-occlusive disease caused by Gynura segetum: a retrospective study. BMC Gastroenterol. 2018;18(1):156.
Article PubMed PubMed Central Google Scholar
Zhuge YZ, Wang Y, Zhang F, Zhu CK, Zhang W, Zhang M, et al. Clinical characteristics and treatment of pyrrolizidine alkaloid-related hepatic vein occlusive disease. Liver Int. 2018;38(10):1867–74.
Article CAS PubMed Google Scholar
Loffroy R. Transjugular intrahepatic portosystemic shunt (TIPS): a major step forward for patients but a growing job for interventional radiologists! Diagn Interv Imaging. 2016;97(11):1069–70.
Article CAS PubMed Google Scholar
Boyer TD. Transjugular intrahepatic portosystemic shunt: current status. Gastroenterology. 2003;124(6):1700–10.
Azoulay D, Castaing D, Lemoine A, Hargreaves GM, Bismuth H. Transjugular intrahepatic portosystemic shunt (TIPS) for severe veno-occlusive disease of the liver following bone marrow transplantation. Bone Marrow Transplant. 2000;25(9):987–92.
Article CAS PubMed Google Scholar
Annaloro C, Robbiolo L, Pozzoli E, Ibatici A, Nicolini A, Salerno F, et al. Four-year survival after trans-jugular intrahepatic porto-systemic shunt for veno-occlusive disease following autologous bone marrow transplantation. Leuk Lymphoma. 2004;45(7):1485–7.
Senzolo M, Riggio O, Primignani M. Italian association for the study of the liver ad h. Vascular disorders of the liver: recommendations from the Italian association for the study of the liver (AISF) ad hoc committee. Dig Liver Dis. 2011;43(7):503–14.
Fagiuoli S, Bruno R, Debernardi Venon W, Schepis F, Vizzutti F, Toniutto P, et al. Consensus conference on TIPS management: techniques, indications, contraindications. Dig Liver Dis. 2017;49(2):121–37.
Zhuge Y, Liu Y, Xie W, Zou X, Xu J, Wang J, et al. Expert consensus on the clinical management of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome. J Gastroenterol Hepatol. 2019;34(4):634–42.
Rajesh S, George T, Philips CA, Ahamed R, Kumbar S, Mohan N, et al. Transjugular intrahepatic portosystemic shunt in cirrhosis: an exhaustive critical update. World J Gastroenterol. 2020;26(37):5561–96.
Article CAS PubMed PubMed Central Google Scholar
Corbacioglu S, Carreras E, Ansari M, Balduzzi A, Cesaro S, Dalle JH, et al. Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation. Bone Marrow Transplant. 2018;53(2):138–45.
Article CAS PubMed Google Scholar
Yoon JH, Yoo KH, Sung KW, Jung CW, Kim JS, Hahn SM, et al. Validation of treatment outcomes according to revised severity criteria from European society for blood and marrow transplantation (EBMT) for sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD). Bone Marrow Transplant. 2019;54(8):1361–8.
Xiao J, Tu J, Zhang H, Zhang F, Zhang W, Xu H, et al. Risk factors of poor prognosis in patients with pyrrolidine alkaloid-induced hepatic sinusoidal obstruction syndrome after transjugular intrahepatic portosystemic shunt. Hepatol Int. 2021;15(3):720–9.
Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res. 2011;46(3):399–424.
Campos-Varela I, Castells L, Dopazo C, Perez-Lafuente M, Allende H, Len O, et al. Transjugular intrahepatic portosystemic shunt for the treatment of sinusoidal obstruction syndrome in a liver transplant recipient and review of the literature. Liver Transpl. 2012;18(2):201–5.
Zhu L, Zhang CY, Li DP, Chen HB, Ma J, Gao H, et al. Tu-San-Qi (Gynura japonica): the culprit behind pyrrolizidine alkaloid-induced liver injury in China. Acta Pharmacol Sin. 2021;42(8):1212–22.
Article CAS PubMed Google Scholar
Webster CR. Hemostatic disorders associated with hepatobiliary disease. Vet Clin North Am Small Anim Pract. 2017;47(3):601–15.
Tripodi A, Caldwell SH, Hoffman M, Trotter JF, Sanyal AJ. Review article: the prothrombin time test as a measure of bleeding risk and prognosis in liver disease. Aliment Pharmacol Ther. 2007;26(2):141–8.
Article CAS PubMed Google Scholar
Peng J, He G, Chen H, Kuang X. Study on correlation between coagulation indexes and disease progression in patients with cirrhosis. Am J Transl Res. 2021;13(5):4614–23.
CAS PubMed PubMed Central Google Scholar
Yang M, Ruan J, Gao H, Li N, Ma J, Xue J, et al. First evidence of pyrrolizidine alkaloid N-oxide-induced hepatic sinusoidal obstruction syndrome in humans. Arch Toxicol. 2017;91(12):3913–25.
Article CAS PubMed Google Scholar
Yang M, Ma J, Ruan J, Ye Y, Fu PP, Lin G. Intestinal and hepatic biotransformation of pyrrolizidine alkaloid N-oxides to toxic pyrrolizidine alkaloids. Arch Toxicol. 2019;93(8):2197–209.
Article CAS PubMed Google Scholar
Hu PF, Xie WF. Corticosteroid therapy in drug-induced liver injury: pros and cons. J Dig Dis. 2019;20(3):122–6.
Zhu H, Chu Y, Huo J, Chen Z, Yang L. Effect of prednisone on transforming growth factor-beta1, connective tissue growth factor, nuclear factor-kappaBp65 and tumor necrosis factor-alpha expression in a murine model of hepatic sinusoidal obstruction syndrome induced by Gynura segetum. Hepatol Res. 2011;41(8):795–803.
Zhang L, Li Q, Makamure J, Zhao D, Liu Z, Zheng C, et al. Transjugular intrahepatic portosystemic shunt for hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum. BMC Gastroenterol. 2021;21(1):26.
Article CAS PubMed PubMed Central Google Scholar
Vizzutti F, Schepis F, Arena U, Fanelli F, Gitto S, Aspite S, et al. Transjugular intrahepatic portosystemic shunt (TIPS): current indications and strategies to improve the outcomes. Intern Emerg Med. 2020;15(1):37–48.
Trebicka J, Macnaughtan J, Schnabl B, Shawcross DL, Bajaj JS. The microbiota in cirrhosis and its role in hepatic decompensation. J Hepatol. 2021;75(Suppl 1):S67–81.
留言 (0)